<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">ANTIMICROB AGENTS CHEMOTHER</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC89787</article-id><article-id pub-id-type="pmcid-ver">PMC89787.1</article-id><article-id pub-id-type="pmcaid">89787</article-id><article-id pub-id-type="pmcaiid">89787</article-id><article-id pub-id-type="pmid">10722486</article-id><article-id pub-id-type="doi">10.1128/aac.44.4.885-890.2000</article-id><article-id pub-id-type="publisher-id">0348</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Experimental Therapeutics</subject></subj-group></article-categories><title-group><article-title>Efficacies of Imipenem, Meropenem, Cefepime, and Ceftazidime in Rats with Experimental Pneumonia Due to a Carbapenem-Hydrolyzing &#946;-Lactamase-Producing Strain of <italic>Enterobacter cloacae</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Mimoz</surname><given-names initials="O">Olivier</given-names></name><xref ref-type="aff" rid="N0x8b57828.0x9c83d58">1</xref><xref ref-type="aff" rid="N0x8b57828.0x9c83d58">2</xref><xref ref-type="aff" rid="N0x8b57828.0x9c83d58">3</xref><xref ref-type="author-notes" rid="FN150">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Leotard</surname><given-names initials="S">Sophie</given-names></name><xref ref-type="aff" rid="N0x8b57828.0x9c83d58">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jacolot</surname><given-names initials="A">Anne</given-names></name><xref ref-type="aff" rid="N0x8b57828.0x9c83d58">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Padoin</surname><given-names initials="C">Christophe</given-names></name><xref ref-type="aff" rid="N0x8b57828.0x9c83d58">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Louchahi</surname><given-names initials="K">Kamel</given-names></name><xref ref-type="aff" rid="N0x8b57828.0x9c83d58">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Petitjean</surname><given-names initials="O">Olivier</given-names></name><xref ref-type="aff" rid="N0x8b57828.0x9c83d58">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nordmann</surname><given-names initials="P">Patrice</given-names></name><xref ref-type="aff" rid="N0x8b57828.0x9c83d58">2</xref></contrib></contrib-group><aff id="N0x8b57828.0x9c83d58"> Service d'Anesth&#233;sie-R&#233;animation, H&#244;pital Paul Brousse, Assistance Publique-H&#244;pitaux de Paris, Facult&#233; de M&#233;decine de Paris-Sud, 94804 Villejuif C&#233;dex,<sup>1</sup> Service de Bact&#233;riologie-Virologie, H&#244;pital de Bic&#234;tre, Assistance Publique-H&#244;pitaux de Paris, Facult&#233; de M&#233;decine de Paris-Sud, 94275 Le Kremlin-Bic&#234;tre C&#233;dex,<sup>2</sup> and  Cr&#233;pit 93 Centre de Recherche en Pathologie Infectieuse et Tropicale, Facult&#233; de M&#233;decine de Paris-Nord, 93009 Bobigny C&#233;dex,<sup>3</sup> France</aff><author-notes><fn id="FN150"><label>*</label><p>Corresponding author. Mailing address: Service d'Anesth&#233;sie-R&#233;animation, H&#244;pital Paul Brousse, 12, ave. Paul Vaillant-Couturier, 94804 Villejuif C&#233;dex, France. Phone: 33 1 45 59 32 19. Fax: 33 1 45 59 38 34. E-mail: <email>olivier.mimoz@pbr.ap-hop-paris.fr</email>.</p></fn></author-notes><pub-date pub-type="ppub"><month>4</month><year>2000</year></pub-date><volume>44</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">2483</issue-id><fpage>885</fpage><lpage>890</lpage><history><date date-type="received"><day>3</day><month>5</month><year>1999</year></date><date date-type="rev-request"><day>5</day><month>10</month><year>1999</year></date><date date-type="accepted"><day>10</day><month>1</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>04</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>12</day><month>09</month><year>2002</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2019-10-31 10:56:17.363"><day>31</day><month>10</month><year>2019</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2000, American Society for Microbiology</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ac000885.pdf"/><abstract><p>The antibacterial activities of imipenem-cilastatin, meropenem-cilastatin, cefepime and ceftazidime against <italic>Enterobacter cloacae</italic> NOR-1, which produces the carbapenem-hydrolyzing &#946;-lactamase NmcA and a cephalosporinase, and against one of its in vitro-obtained ceftazidime-resistant mutant were compared by using an experimental model of pneumonia with immunocompetent rats. The MICs of the &#946;-lactams with an inoculum of 5 log<sub>10</sub> CFU/ml were as follows for <italic>E. cloacae</italic> NOR-1 and its ceftazidime-resistant mutant, respectively: imipenem, 16 and 128 &#956;g/ml, meropenem, 4 and 32 &#956;g/ml, cefepime, &lt;0.03 and 1 &#956;g/ml, and ceftazidime, 1 and 512 &#956;g/ml. The chromosomally located cephalosporinase and carbapenem-hydrolyzing &#946;-lactamase NmcA were inducible by cefoxitin and meropenem in <italic>E. cloacae</italic> NOR-1, and both were stably overproduced in the ceftazidime-resistant mutant. Renal impairment was induced (uranyl nitrate, 1 mg/kg of body weight) in rats to simulate the human pharmacokinetic parameters for the &#946;-lactams studied. Animals were intratracheally inoculated with 8.5 log<sub>10</sub> CFU of <italic>E. cloacae</italic>, and therapy was initiated 3 h later. At that time, animal lungs showed bilateral pneumonia containing more than 6 log<sub>10</sub> CFU of <italic>E. cloacae</italic> per g of tissue. Despite the relative low MIC of meropenem for <italic>E. cloacae</italic> NOR-1, the carbapenem-treated rats had no decrease in bacterial counts in their lungs 60 h after therapy onset compared to the counts for the controls, regardless of whether <italic>E. cloacae</italic> NOR-1 or its ceftazidime-resistant mutant was inoculated. A significant decrease in bacterial titers was observed for the ceftazidime-treated rats infected with <italic>E. cloacae</italic> NOR-1 only. Cefepime was the only &#946;-lactam tested effective as treatment against infections due to <italic>E. cloacae</italic> NOR-1 or its ceftazidime-resistant mutant.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>